Ribobay Pharma, a Chinese biopharmaceutical contract research, development, and manufacturing organization (CRDMO) and a spin-off company of General Biol (Anhui) Co., Ltd, has tapped Cytvia’s first FlexFactory platform for oligonucleotide (oligo) manufacturing to provide cGMP-level oligo CRDMO services to the world.
 
It is scheduled to commence manufacturing in June and expects to produce several hundred kilograms of pharmaceutical oligo per year, bringing increased reliability, speed, and efficiency to the development of novel therapies.
 
Jingui Yong, General Manager of Ribobay Pharma, says: “With the support of Cytiva, we will rapidly expand our oligo CRDMO business by manufacturing high-quality and diversified innovative drugs, as well as new vaccine adjuvant (CpG-ODNs) for global customers. We look forward to building on synergies and creating more value with our collaborators.”
 
With the FlexFactory platform, Ribobay Pharma can better serve its customers, providing process development support, optimization, method development, pilot production services, and customized manufacturing services.
 
Allen Li, President of Cytiva in China, says: “It’s an honor to work with Ribobay Pharma to roll out our very first FlexFactory platform for oligos. We will continue facilitating more Chinese companies to navigate the global market, and ultimately help improve the accessibility of life-changing therapies for global patients.”
 
The collaboration between Cytiva and Ribobay Pharma is a response to market needs and developmental bottlenecks. Cytiva provides Ribobay Pharma with integrated services, from factory design to equipment and technologies that enable cGMP manufacturing.